![CB,HBI,HBN目錄 2019.03 補P2 - STAIRSCBI,HBI,HBN_Series_50Hz,60Hz.pdf · ISO 9906 Annex A CB 12 60 Hz 2 0 50 10 20 30 40 50 0 Q[m3/h] 2 4 6 20 40 NPSH Eta 100 150 60 250 60 CB 12-40](https://static.fdocument.org/doc/165x107/5e3d243b5e2a1f7b67609482/cbhbihbnceoe-201903-eoep2-cbihbihbnseries50hz60hzpdf-iso-9906-annex.jpg)
Poster 411P PHARMACOLOGICAL ACTIVITY OF CB-103 – AN …€¦ · Table 1: Activity of CB-103 in...
1
Table 1: Activity of CB-103 in panel of cancer cell lines (IC50 < 10 μM) Dirk Weber 1 , Raj Lehal 1 , Viktoras Frismantas 2 , Jean-Pierre Bourquin 2 , Michael Bauer 1 , Maximilien Murone 1 , Freddy Radtke 3 1 Cellestia Biotech AG, Basel, CH, 2 University Children’s Hospital, Zurich, CH, 3 Swiss Institute for Experimental Cancer Research, EPFL, CH BACKGROUND NOTCH signalling is a developmental pathway known to play critical roles during embryonic development as well as for the regulation of self-renewing tissues. Aberrant activation of NOTCH signalling leads to deregulation of the self-renewal process resulting in sustained proliferation, evasion of cell death, loss of differentiation capacity, invasion and metastasis, all of which are hallmarks of cancer. When the NOTCH pathway is activated by genetic lesions (overexpression of NOTCH ligands/ receptors, GOF mutations in NOTCH receptors as well as chromosomal translocations), it becomes a major driver for NOTCH-dependent cancers and resistance to standard of care. OBJECTIVES Several therapeutic NOTCH inhibitors are currently in clinical testing with a) mAbs against NOTCH ligands and receptors and b) gamma-secretase inhibitors (GSIs). However clinical activity and exposure of these in clinical studies were limited due to GI- tract toxicities. In solid tumour and haematological malignancies with constitutive NOTCH activation (gene fusion due to chromosomal translocations or NOTCH mutations), mAbs and GSIs will have limited clinical benefits. Here we report, discovery and development of a novel orally active small molecule protein- protein interaction inhibitor (CB-103) of the NOTCH pathway. CB-103 is a pan-NOTCH inhibitor with a novel mode of action, directly targeting the NOTCH transcriptional activation complex. We will further present the in vitro and in vivo pharmacological characterization of CB-103. SUMMARY We demonstrate that in vitro CB-103 potently inhibits NOTCH signalling in various lymphoma, leukaemia and solid tumour cell lines (e.g. breast cancer, lung, osteosarcoma, cervical), and ex vivo in T-ALL blasts derived from relapsed/refractory patients. In addition, CB- 103 exhibited anti-tumor efficacy in in vivo models of NOTCH-driven T-ALL using T-ALL cell lines and PDX models derived from T-ALL and TNBC. RESULTS CONCLUSIONS REFERENCES MATERIALS & METHODS Pharmacodynamic (PD) studies were conducted to investigate CB-103 in relation to its desired therapeutic effect in blood and solid cancers as a pan-NOTCH pathway inhibitor. Regarding the PD effect, in vitro studies showed for CB-103 a dose-dependent decrease in NOTCH signalling with a unique mechanism compared to GSIs and mAbs. The NOTCH inhibitory potential of CB-103 was further confirmed by downregulation of NOTCH target genes in human T-cell acute lymphoblastic leukaemia (T- ALL), suggesting therapeutic efficacy in T-ALL. In a panel of 123 cancer cell lines, CB-103 was active in 24 cell lines matching to tumour types with known activated NOTCH lesions. Moreover, CB-103 showed activity in the Triple-Negative Breast Ca (TNBC) HCC1187 cell line (resistant to GSI due to NOTCH 2 chromosomal translocation). PD and toxicology studies have revealed an excellent efficacy and safety profile in the expected human therapeutic dose range. Clinical development of CB-103 with a first-in- human Phase I/IIA clinical study in advanced or metastatic solid tumours, lymphoma subtypes and multiple myeloma is under Health Authority review. 1. Andersson ER, Lendahl U. 2014. Therapeutic modulation of NOTCH signaling-are we there yet?; Nature reviews Drug discovery 13: 357-378. 2. Reedijk M. High-level Co-expression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival. Cancer Res. 2005;65(18):8530-8537. 3. Ferrarotto R, Mitani Y, Diao L, et al. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017;35(3):352-360. PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION Figure 1: Patients with NOTCH- driven cancer have shorter survival Poster 411P Figure 5: Ex-vivo response to CB-103 in leukaemic blasts from T-ALL patients Figure 3: CB-103 blocks NOTCH signalling in human T-ALL leukaemia cell lines • CB-103 blocks NOTCH signalling in human T-ALL cell lines harboring GOF mutations in NOTCH1 receptor (Inhibition of target gene expression at mRNA and protein levels) Figure 4: CB-103 inhibits NOTCH in GSI/ mAbs resistant human cancer cell lines • Downregulation of NOTCH Target Genes HES1 and cMYC in NOTCH activated RPMI8402, DND41 and HCC1187 by CB-103, but not GSIs • Human T-ALL cell lines RPMI8402/DND41 engineered to express constitutive NICD1 • Triple Negative Breast Cancer HCC1187 constitutively NOTCH2 active and GSI resistant Figure 6: CB-103 reduces tumour growth in a GSI-resistant Triple Negative Human Breast Cancer (HCC1187) • Responsiveness of CB-103 correlates to level of NOTCH activation (NICD1 expression) • Combi: 100-1000x enhancement of chemo and 75% survival benefit at 25 mpk • Selective killing of leukemic cells in NOTCH positive disease • Screening of > 120 cell lines for CB-103 activity (IC50 values) • 24 / 120 cell lines showed IC50 < 10 μM • Several solid tumours, lymphomas, ALL, CLL and MM among responding cell lines Figure 7: Clinical Development for CB-103 will be initiated with first-in- human phase I/IIA study (under preparation, planned start Q3-2017) • Anti-tumor efficacy (TGI: 80-90%) of CB-103 in NOTCH2-driven and GSI resistant model of TNBC CONTACT Cellestia Biotech AG, Hochbergerstrasse 60C, CH-4057 Basel, CH Web: www.cellestia.com Mail: [email protected] Breast Cancer [Overall Survival] Adenoid Cystic Carcinoma [Overall Survival] Figure 2: CB-103 blocks NOTCH pathway at the transcription complex level • CB-103 is a first-in-class pan-NOTCH inhibitor • CB-103 is specific for NOTCH pathway and inhibits NOTCH target genes • CB-103 overcomes crosstalk and escape mechanisms of NOTCH and other pathways INDICATIONS CELL LINES NOTCH STATUS (lit. based) CB-103 IC50 (µM) GSI RO4929097 IC50 (µM) Breast HCC 1569 Positive 5.3 100 HCC1187 Positive 5 >10 Lung NCI-H1581 NA 5.5 60 Cervix C33a Positive 1.2 >100 Neuroblastoma SK-N-MC Positive 1.5 44 Osteosarcoma SK-ES-1 Positive 1.9 >100 Endometrium Ishikawa Positive 3 81 CLL JVM-3 NA 7.2 65 MM KMS-12-BM NA 8.2 >100 Lymphoma NALM-6 NA 1.1 63 U-937 Positive 9.4 59 Mantle cell lymphoma REC-1 Positive 1 --- T-ALL RPMI8402 Positive 0.7 5 KOPTK1 Positive 1 5 CUTL1 Positive 3 >10 Cervical HeLa Negative >100 >100 Reedjik et al. Cancer Research 2005
Transcript of Poster 411P PHARMACOLOGICAL ACTIVITY OF CB-103 – AN …€¦ · Table 1: Activity of CB-103 in...
Table 1: Activity of CB-103 in panel of cancer cell lines (IC50 < 10 μM)
Dirk Weber1, Raj Lehal1, Viktoras Frismantas2, Jean-Pierre Bourquin2, Michael Bauer1, Maximilien Murone1, Freddy Radtke3
1 Cellestia Biotech AG, Basel, CH, 2 University Children’s Hospital, Zurich, CH, 3 Swiss Institute for Experimental Cancer Research, EPFL, CH
BACKGROUNDNOTCH signalling is a developmental pathway known to playcritical roles during embryonic development as well as for theregulation of self-renewing tissues. Aberrant activation ofNOTCH signalling leads to deregulation of the self-renewalprocess resulting in sustained proliferation, evasion of cell death,loss of differentiation capacity, invasion and metastasis, all ofwhich are hallmarks of cancer. When the NOTCH pathway isactivated by genetic lesions (overexpression of NOTCH ligands/receptors, GOF mutations in NOTCH receptors as well aschromosomal translocations), it becomes a major driver forNOTCH-dependent cancers and resistance to standard of care.
OBJECTIVESSeveral therapeutic NOTCH inhibitors are currently in clinicaltesting with a) mAbs against NOTCH ligands and receptors andb) gamma-secretase inhibitors (GSIs). However clinical activityand exposure of these in clinical studies were limited due to GI-tract toxicities. In solid tumour and haematological malignancieswith constitutive NOTCH activation (gene fusion due tochromosomal translocations or NOTCH mutations), mAbs andGSIs will have limited clinical benefits. Here we report, discoveryand development of a novel orally active small molecule protein-protein interaction inhibitor (CB-103) of the NOTCH pathway.CB-103 is a pan-NOTCH inhibitor with a novel mode of action,directly targeting the NOTCH transcriptional activation complex.We will further present the in vitro and in vivo pharmacologicalcharacterization of CB-103.
SUMMARYWe demonstrate that in vitro CB-103 potently inhibitsNOTCH signalling in various lymphoma, leukaemia andsolid tumour cell lines (e.g. breast cancer, lung,osteosarcoma, cervical), and ex vivo in T-ALL blastsderived from relapsed/refractory patients. In addition, CB-103 exhibited anti-tumor efficacy in in vivo models ofNOTCH-driven T-ALL using T-ALL cell lines and PDXmodels derived from T-ALL and TNBC.
RESULTS
CONCLUSIONS REFERENCES
MATERIALS & METHODSPharmacodynamic (PD) studies were conducted to investigateCB-103 in relation to its desired therapeutic effect in blood andsolid cancers as a pan-NOTCH pathway inhibitor. Regarding thePD effect, in vitro studies showed for CB-103 a dose-dependentdecrease in NOTCH signalling with a unique mechanismcompared to GSIs and mAbs. The NOTCH inhibitory potential ofCB-103 was further confirmed by downregulation of NOTCHtarget genes in human T-cell acute lymphoblastic leukaemia (T-ALL), suggesting therapeutic efficacy in T-ALL. In a panel of 123cancer cell lines, CB-103 was active in 24 cell lines matching totumour types with known activated NOTCH lesions. Moreover,CB-103 showed activity in the Triple-Negative Breast Ca (TNBC)HCC1187 cell line (resistant to GSI due to NOTCH 2chromosomal translocation).
PD and toxicology studies have revealed anexcellent efficacy and safety profile in theexpected human therapeutic dose range.Clinical development of CB-103 with a first-in-human Phase I/IIA clinical study in advancedor metastatic solid tumours, lymphomasubtypes and multiple myeloma is underHealth Authority review.
1. Andersson ER, Lendahl U. 2014. Therapeutic modulation of NOTCH signaling-are we there yet?; Nature reviews Drug discovery 13: 357-378.
2. Reedijk M. High-level Co-expression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival. Cancer Res. 2005;65(18):8530-8537.
3. Ferrarotto R, Mitani Y, Diao L, et al. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017;35(3):352-360.
PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION
Figure 1: Patients with NOTCH-driven cancer have shorter survival
Poster 411P
Figure 5: Ex-vivo response to CB-103 in leukaemicblasts from T-ALL patients
Figure 3: CB-103 blocks NOTCH signalling in human T-ALL leukaemia cell lines
• CB-103 blocks NOTCH signalling in human T-ALL cell lines harboring GOF mutations in NOTCH1 receptor (Inhibition of target gene expression at mRNA and protein levels)
Figure 4: CB-103 inhibits NOTCH in GSI/ mAbs resistant human cancer cell lines
• Downregulation of NOTCH Target Genes HES1 and cMYC in NOTCH activated RPMI8402, DND41 and HCC1187 by CB-103, but not GSIs
• Human T-ALL cell lines RPMI8402/DND41engineered to express constitutive NICD1
• Triple Negative Breast Cancer HCC1187constitutively NOTCH2 active and GSI resistant
Figure 6: CB-103 reduces tumour growth in a GSI-resistant Triple Negative Human Breast Cancer (HCC1187)
• Responsiveness of CB-103 correlates to level of NOTCH activation (NICD1 expression)
• Combi: 100-1000x enhancement of chemo and 75% survival benefit at 25 mpk
• Selective killing of leukemic cells in NOTCH positive disease
• Screening of > 120 cell lines for CB-103 activity (IC50 values)• 24 / 120 cell lines showed IC50 < 10 μM• Several solid tumours, lymphomas, ALL, CLL and MM among
responding cell lines
Figure 7: Clinical Development for CB-103 will be initiated with first-in-human phase I/IIA study (under preparation, planned start Q3-2017)
• Anti-tumor efficacy (TGI: 80-90%) of CB-103 in NOTCH2-driven and GSI resistant model of TNBC
CONTACTCellestia Biotech AG, Hochbergerstrasse 60C, CH-4057 Basel, CHWeb: www.cellestia.comMail: [email protected]
Breast Cancer[Overall Survival]
Adenoid Cystic Carcinoma[Overall Survival]
Figure 2: CB-103 blocks NOTCH pathway at the transcription complex level
• CB-103 is a first-in-class pan-NOTCH inhibitor • CB-103 is specific for NOTCH pathway and
inhibits NOTCH target genes• CB-103 overcomes crosstalk and escape
mechanisms of NOTCH and other pathways
INDICATIONS CELL LINES NOTCH STATUS(lit. based)
CB-103 IC50 (µM)
GSI RO4929097 IC50 (µM)
Breast HCC 1569 Positive 5.3 100
HCC1187 Positive 5 >10
Lung NCI-H1581 NA 5.5 60
Cervix C33a Positive 1.2 >100
Neuroblastoma SK-N-MC Positive 1.5 44
Osteosarcoma SK-ES-1 Positive 1.9 >100
Endometrium Ishikawa Positive 3 81
CLL JVM-3 NA 7.2 65
MM KMS-12-BM NA 8.2 >100
Lymphoma NALM-6 NA 1.1 63
U-937 Positive 9.4 59
Mantle cell lymphoma
REC-1 Positive 1 ---
T-ALL RPMI8402 Positive 0.7 5
KOPTK1 Positive 1 5
CUTL1 Positive 3 >10
Cervical HeLa Negative >100 >100
Reedjik et al.Cancer Research 2005
![r l SSN -2230 46 Journal of Global Trends in … M. Nagmoti[61] Bark Anti-Diabetic Activity Anti-Inflammatory activity Anti-Microbial Activity αGlucosidase & αAmylase inhibitory](https://static.fdocument.org/doc/165x107/5affe29e7f8b9a256b8f2763/r-l-ssn-2230-46-journal-of-global-trends-in-m-nagmoti61-bark-anti-diabetic.jpg)
